T. Rowe Price Associates
INDV icon

T. Rowe Price Associates’s Indivior Pharmaceuticals INDV Stock Holding History

T. Rowe Price Associates’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.2M Buy
955,110
+816,160
+587% +$29.6M ﹤0.01% 961
2026
Q1 		$4.24M Buy
138,950
+24,043
+21% +$794K ﹤0.01% 1488
2025
Q4 		$4.12M Buy
114,907
+28,746
+33% +$878K ﹤0.01% 1461
2025
Q3 		$2.08M Buy
86,161
+25,596
+42% +$536K ﹤0.01% 1715
2025
Q2 		$893K Buy
+60,565
New +$705K ﹤0.01% 2036

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's INDV Position: Q2 2026 in Review

T. Rowe Price Associates increased its Indivior Pharmaceuticals (INDV) stake by 587% in Q2 2026, buying an estimated $29.6M and bringing the position to 955,110 shares worth $39.2M. The position accounts for ﹤0.01% of the portfolio, ranked #961.

T. Rowe Price Associates first reported a position in INDV in Q2 2025 and has held it in 5 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • T. Rowe Price Associates held 955,110 shares of Indivior Pharmaceuticals worth $39.2M as of Q2 2026.
  • T. Rowe Price Associates bought 816,160 Indivior Pharmaceuticals shares in Q2 2026, an estimated $29.6M.
  • Indivior Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #961 holding.
  • T. Rowe Price Associates first reported a position in Indivior Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.